Please login to the form below
Donanemab
This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.
Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
Trial will evaluate donanemab in participants at risk for cognitive and functional decline related to Alzheimer’s. ... Donanemab is also being studied in the ongoing phase 3 TRAILBLAZER-ALZ 2 study in early symptomatic Alzheimer’s disease patients.
Latest news
-
Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab
The US Food and Drug Administration (FDA) has granted Eli Lilly’s investigational Alzheimer’s disease drug donanemab a breakthrough therapy designation (BTD). ... The study enrolled a total of 257 patients, with 131 assigned to receive donanemab and
-
Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease
this did not translate to statistical significance between the donanemab-treated and placebo groups. ... The study enrolled a total of 257 patients, with 131 assigned to receive donanemab and 126 to receive placebo.
-
Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes
Drug demonstrated a 'significant' slowing of cognitive decline. Eli Lilly’s amyloid-targeting antibody donanemab has shown promise in the treatment of Alzheimer’s disease, sending its stocks soaring and renewing ... function’. In other measures,
-
Germany’s Vivoryon raises €43m for Alzheimer’s drug trial
Eli Lilly is developing an antibody drug against it – called donanemab – which has reached the phase 2 testing stage.
-
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
Its pipeline currently includes solanezumab for Alzheimer’s – which has already failed earlier phase 3 trials – along with two antibodies for the disease in mid-stage testing (donanemab and zagotenemab) and
Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab
Germany’s Vivoryon raises €43m for Alzheimer’s drug trial
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Recently published study results for aducanumab and donanemab, both antibodies against amyloid, showed effects that indicated some improvement in cognition and daily function in patients with early Alzheimer’s. ... In the aforementioned aducanumab and
Alzheimer’s: the search for a cure
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- World Mental Health Day is on 10 October
- The Future of eHealth: Contactless Health Monitoring
- Beyond yoga and smoothies – providing real support for employee well-being
- The Real-Time Health System: Accelerating Workflows with Data
- NICE looks internally for new chief executive
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
